- Home
- SDGR vs TSHA Comparison
SDGR vs TSHA Comparison
Compare SDGR & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- TSHA
- Stock Information
- Founded
- SDGR 1990
- TSHA 2019
- Country
- SDGR United States
- TSHA United States
- Employees
- SDGR N/A
- TSHA N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- SDGR Health Care
- TSHA Health Care
- Exchange
- SDGR Nasdaq
- TSHA Nasdaq
- Market Cap
- SDGR 1.4B
- TSHA 1.4B
- IPO Year
- SDGR 2020
- TSHA 2020
- Fundamental
- Price
- SDGR $20.87
- TSHA $4.93
- Analyst Decision
- SDGR Buy
- TSHA Strong Buy
- Analyst Count
- SDGR 8
- TSHA 9
- Target Price
- SDGR $26.75
- TSHA $10.00
- AVG Volume (30 Days)
- SDGR 1.3M
- TSHA 11.2M
- Earning Date
- SDGR 11-05-2025
- TSHA 11-04-2025
- Dividend Yield
- SDGR N/A
- TSHA N/A
- EPS Growth
- SDGR N/A
- TSHA N/A
- EPS
- SDGR N/A
- TSHA N/A
- Revenue
- SDGR $237,917,000.00
- TSHA $8,098,000.00
- Revenue This Year
- SDGR $22.73
- TSHA N/A
- Revenue Next Year
- SDGR $19.85
- TSHA N/A
- P/E Ratio
- SDGR N/A
- TSHA N/A
- Revenue Growth
- SDGR 18.59
- TSHA N/A
- 52 Week Low
- SDGR $16.60
- TSHA $1.05
- 52 Week High
- SDGR $28.47
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- SDGR 50.88
- TSHA 58.95
- Support Level
- SDGR $19.99
- TSHA $4.70
- Resistance Level
- SDGR $23.02
- TSHA $5.25
- Average True Range (ATR)
- SDGR 1.12
- TSHA 0.35
- MACD
- SDGR 0.03
- TSHA -0.07
- Stochastic Oscillator
- SDGR 47.94
- TSHA 46.37
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.